Roche and Hitachi High-Tech extend 46-year partnership

Roche and Hitachi High-Tech have announced the extension of the partnership between the two companies, committing to at least 10 years of additional collaboration. Bringing together Roche and Hitachi’s expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the long-lasting partnership.

Together, the companies have delivered significant innovations that paved the way for industry-leading in-vitro diagnostic solutions. From revolutionising the clinical laboratory with the world's first multi-channel analyser, to the automation of immunology, the collaboration has led to groundbreaking innovations that have enabled laboratories and healthcare systems to overcome delivery challenges and get patients the care they need.

"I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care," commented Palani Kumaresan, Head of Roche Diagnostic Solutions. "Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients' needs."

"Hitachi High-Tech and Roche have worked together to expand in the field of in-vitro diagnostics by boldly pursuing innovations. The renewal of this agreement demonstrates both companies' commitment to the future of the global diagnostics market. We look forward to continuing to work together to further expand the utility of in-vitro diagnostics in healthcare," said Taku Sakazume, Executive Officer, Head of Diagnostic System Business, Hitachi High-Tech Corporation.

Later this year, Roche and Hitachi High-Tech plan to introduce exciting new innovations including the new analytical units cobas c 703 and cobas ISE neo for cobas pro integrated solutions, to increase potential testing capacity for laboratories and provide accurate and timely diagnosis for millions of patients around the world. By the end of the year, the introduction of the new cobas Mass Spec solution will mark another exciting milestone by integrating fully-automated mass spectrometry into the routine laboratory. This will make this gold standard technology available to more people around the world across various clinical applications.


Latest Issues

The Power to Disrupt - Clinical Diagnostics Expo UK

15 Hatfields
16 September, 2024

Microbe Conference 2024

Crowne Plaza Hotel, Sheffield, UK
20-22 September, 2024

Cardiac Marker Dialogues: Cardiac Biomarkers in Real Time – Experiences and Opportunities

Hilton Glasgow, 1 William Street, Glasgow, Scotland, G3 8HT
26-27 September, 2024

UK NEQAS: Navigating Quality Standards in Point of Care Testing

The Hyatt Regency Hotel, Birmingham, UK
23 October, 2024